MD Anderson Cancer: Glioblastoma Study Discovers Protective Role of Metabolic Enzyme, Revealing a Novel Therapeutic Target
May 27, 2021
May 27, 2021
HOUSTON, Texas, May 27 (TNSJou) -- The University of Texas's MD Anderson Cancer Center issued the following news release on May 26, 2021:
Researchers at The University of Texas MD Anderson Cancer Center have discovered a novel function for the metabolic enzyme medium-chain acyl-CoA dehydrogenase (MCAD) in glioblastoma (GBM). MCAD prevents toxic lipid buildup, in addition to its normal role in energy production, so targeting MCAD causes irreversible damage and cell death specifically . . .
Researchers at The University of Texas MD Anderson Cancer Center have discovered a novel function for the metabolic enzyme medium-chain acyl-CoA dehydrogenase (MCAD) in glioblastoma (GBM). MCAD prevents toxic lipid buildup, in addition to its normal role in energy production, so targeting MCAD causes irreversible damage and cell death specifically . . .